SCHEMBL5707477

SCHEMBL5707477

CON(C)C(=O)C1=CCC2C3CCc4cc(NS(=O)(=O)O)ccc4C3CC[C@]12C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 5/20 0.57
ESR1 P03372 4/20 0.51
ABCC4 O15439 1/20 0.47
CYP2C9 P11712 1/20 0.47
ABCC1 P33527 1/20 0.47
SLCO1B1 Q9Y6L6 1/20 0.47
AKR1C3 P42330 5/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
HSD17B1 P14061 2/20 0.45
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ESR2 Q92731 2/20 0.44
CYP3A4 P08684 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
AKR1B10 O60218 1/20 0.43
SHBG P04278 1/20 0.43
CYP1A2 P05177 1/20 0.43
PGR P06401 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5707471 1.00 STS (0.57) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL5707639 0.86 ESR1 (0.54) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL5707636 0.86 ESR1 (0.54) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL5707607 0.84 ESR1 (0.56) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL5707602 0.84 ESR1 (0.56) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL712799 0.77 STS (0.70) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL6869676 0.77 STS (0.70) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL7214587 0.75 STS (0.65) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL5707458 0.75 STS (0.85) STSESR1ABCC4CYP2C9ABCC1
SCHEMBL5707460 0.75 STS (0.85) STSESR1ABCC4CYP2C9ABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147124-B1 STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME UNIV HOLY GHOST DUQUESNE (US) 2006-08-30 EP disclosed
US-6436918-B1 SULFAMATE- AND AMINOCARBONYL- SUBSTITUTED STEROID RING SYSTEM HAVING 4 ATTACHED RINGS; THERAPEUTIC AND PROPHYLACTIC TREATMENTS FOR ESTROGEN DEPENDENT ILLNESSES. DUQUESNE UNIVERSITY OF THE HOLY GHOST 2002-08-20 US disclosed
US-20020068726-A1 Steroid sulfatase inhibitors and methods for making and using the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2002-06-06 US disclosed
US-6376687-B1 THERAPY FOR ESTROGEN SENSITIVE DISEASES DUQUESNE UNIVERSITY OF THE HOLY GHOST 2002-04-23 US disclosed
EP-1147124-A2 STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) 2001-10-24 EP disclosed
WO-2000043408-A2 STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068726-A1 Steroid sulfatase inhibitors and methods for making and using the same STS, HSD17B11, CYP21A2 STS 1/4885ESR1 58/4885ABCC4 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.